According to Zhitong Finance App News, Guobang Pharmaceutical (605507.SH) disclosed its 2026 semi-annual report. During the reporting period, the company achieved revenue of 3.142 billion yuan, an increase of 3.84%; net profit attributable to shareholders of listed companies was 341 million yuan, a year-on-year decrease of 25.07%; deducted non-net profit of 321 million yuan, a year-on-year decrease of 26.46%; and basic earnings per share were 0.44 yuan.
During the reporting period, the dominant position of pharmaceutical raw materials continued to be stable and resilient. The specialty ingredient telamycin continued to be released, and sales increased 310% year over year; the animal protection business benefited from the recovery of downstream aquaculture, and the industry bottom was consolidated. Flupenicol shipped more than 2,500 tons in the first half of the year, maintaining a rapid growth rate of more than 30% for many years, and the market share stabilized at the top of the world; the plant protection business rapidly developed the market. The quality certification for 7 key customers was added in the first half of the year. It has successfully entered international agrochemical giants such as BASF, Bayer, and Syngenta to build a second company Growth curve; fine chemical trimethyl borate sales It reached a record high. Relying on the existing piperazine industry base and extending to the field of electronic chemicals, hydroxyethyl piperazine has been successfully piloted.
In the first half of the year, the company continued to strengthen scientific research and made continuous breakthroughs in innovative business. Relying on the company's world-leading advantages in the borohydride industry, we have built a high-tech industrial platform for new boron-based materials. Sodium boron deuteride broke foreign monopolies and was successfully developed by laboratories. It is currently in the industrial construction stage. The high strategic value products Na¹ and Na¹ BH4 already have small-batch production capacity.